# Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients

> **NCT02940730** · PHASE4 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 10 (actual)

## Conditions studied

- Infectious Peritonitis

## Interventions

- **DRUG:** Dalbavancin via Intravenous Administration
- **DRUG:** Dalbavancin via Intraperitoneal Administration

## Key facts

- **NCT ID:** NCT02940730
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-01
- **Primary completion:** 2018-06-18
- **Final completion:** 2018-06-18
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02940730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02940730, "Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02940730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*